Alector (ALEC) Set to Announce Quarterly Earnings on Thursday

Alector (NASDAQ:ALEC) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $2.38 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. The business had revenue of $3.32 million during the quarter, compared to the consensus estimate of $1.71 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. On average, analysts expect Alector to post ($0.47) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Alector Trading Up 7.1%

NASDAQ:ALEC opened at $2.25 on Thursday. Alector has a 52-week low of $1.09 and a 52-week high of $2.76. The company has a quick ratio of 5.26, a current ratio of 5.26 and a debt-to-equity ratio of 0.80. The stock has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $2.02. The company has a market capitalization of $251.24 million, a PE ratio of -2.05 and a beta of 0.62.

Insiders Place Their Bets

In related news, CFO Neil Berkley sold 29,251 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $77,807.66. Following the sale, the chief financial officer owned 350,649 shares of the company’s stock, valued at $932,726.34. This trade represents a 7.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Arnon Rosenthal sold 72,606 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total value of $193,131.96. Following the sale, the chief executive officer directly owned 2,294,600 shares in the company, valued at approximately $6,103,636. The trade was a 3.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 111,303 shares of company stock valued at $295,633. Insiders own 8.30% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on ALEC shares. Weiss Ratings upgraded shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Morgan Stanley upped their price target on shares of Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a report on Tuesday, October 6th. UBS Group reiterated a “neutral” rating and issued a $1.50 price target on shares of Alector in a research report on Tuesday, October 6th. Finally, HC Wainwright raised their price objective on shares of Alector from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.62.

About Alector

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.